{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T19:25:44Z","timestamp":1789500344107,"version":"build-2803163510"},"reference-count":43,"publisher":"Japan Society of Histochemistry & Cytochemistry","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Histochem. Cytochem.","Acta Histochemica et Cytochemica","Acta Histochem. Cytochem"],"published-print":{"date-parts":[[2025,2,27]]},"DOI":"10.1267\/ahc.24-00056ep","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T22:12:21Z","timestamp":1738879941000},"page":"1-8","source":"Crossref","is-referenced-by-count":10,"title":["On the Similarity Between Postpartum Autoimmune Abnormalities and Immune-Related Adverse Events (irAE) by Immune Checkpoint Inhibitors (ICI): The Placenta as a PD-L1-Rich Immune-Tolerant Organ"],"prefix":"10.1267","volume":"58","author":[{"given":"Riko","family":"Kitazawa","sequence":"first","affiliation":[{"name":"Department of Molecular Pathology, Ehime University Graduate School of Medicine"},{"name":"Division of Diagnostic Pathology, Ehime University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Kitazawa","sequence":"additional","affiliation":[{"name":"Department of Molecular Pathology, Ehime University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"334","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1 Alijotas-Reig, J., Llurba, E. and Gris, J. M. (2014) Potentiating maternal immune tolerance in pregnancy: a new challenging role for regulatory T cells. Placenta 35; 241\u2013248.","DOI":"10.1016\/j.placenta.2014.02.004"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Amin, S., Peterson, E. J., Reed, A. M. and Mueller, D. L. (2011) Pregnancy and rheumatoid arthritis: insights into the immunology of fetal tolerance and control of autoimmunity. Curr. Rheumatol. Rep. 13; 449\u2013455.","DOI":"10.1007\/s11926-011-0199-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Burlingham, W. J. (2024) Extracellular vesicles in fetal-maternal immune tolerance. Biomed. J. 47; 100785.","DOI":"10.1016\/j.bj.2024.100785"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Caulfield, J. I., Aizenbud, L., Perdigoto, A. L., Meffre, E., Jilaveanu, L., Michalek, D. A., et al. (2023) Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. J. Immunother. Cancer 11; e006570.","DOI":"10.1136\/jitc-2022-006570"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Chamoto, K., Al-Habsi, M. and Honjo, T. (2017) Role of PD-1 in Immunity and Diseases. Curr. Top. Microbiol. Immunol. 410; 75\u201397.","DOI":"10.1007\/82_2017_67"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chen, T. W., Razak, A. R., Bedard, P. L., Siu, L. L. and Hansen, A. R. (2015) A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann. Oncol. 26; 1824\u20131829.","DOI":"10.1093\/annonc\/mdv182"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., et al. (2021) PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat. Rev. Clin. Oncol. 18; 345\u2013362.","DOI":"10.1038\/s41571-021-00473-5"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Durgam, S. S., Alegre, M. L. and Chong, A. S. (2022) Toward an understanding of allogeneic conflict in pregnancy and transplantation. J. Exp. Med. 219; e20211493.","DOI":"10.1084\/jem.20211493"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Ebi, N., Inoue, H., Igata, F., Okuma, R., Kinoshita, E., Kawabata, T., et al. (2024) Clinical Association Between Immune-related Adverse Events and Treatment Efficacy in Patients With Non-small-cell Lung Cancer Treated With Nivolumab-Ipilimumab-based Therapy. Anticancer Res. 44; 3087\u20133095.","DOI":"10.21873\/anticanres.17122"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Fife, B. T. and Bluestone, J. A. (2008) Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev. 224; 166\u2013182.","DOI":"10.1111\/j.1600-065X.2008.00662.x"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Gandarillas, S., Newland, E. S., Toppmeyer, D., Stephenson, R., Denzin, L. and Dasgeb, B. (2023) HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment. Front. Med. (Lausanne). 10; 1288844.","DOI":"10.3389\/fmed.2023.1288844"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Guerin, L. R., Prins, J. R. and Robertson, S. A. (2009) Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment? Hum. Reprod. Update 15; 517\u2013535.","DOI":"10.1093\/humupd\/dmp004"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hamanishi, J., Mandai, M., Matsumura, N., Abiko, K., Baba, T. and Konishi, I. (2016) PD-1\/PD-L1 blockade in cancer treatment: perspectives and issues. Int. J. Clin. Oncol. 21; 462\u2013473.","DOI":"10.1007\/s10147-016-0959-z"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hatakeyama, Y., Ohnishi, H., Suda, K., Okamura, K., Shimada, T. and Yoshimura, S. (2019) Nivolumab-induced acute-onset type 1 diabetes mellitus as an immune-related adverse event: A case report. J. Oncol. Pharm. Pract. 25; 2023\u20132026.","DOI":"10.1177\/1078155218816777"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15 Jayathilaka, B., Mian, F., Franchini, F., Au-Yeung, G. and IJzerman, M. (2024) Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: a systematic review. Br. J. Cancer. doi: 10.1038\/s41416-024-02887-1. Online ahead of print.","DOI":"10.1038\/s41416-024-02887-1"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16 Kawabata, Y., Nishida, N., Awata, T., Kawasaki, E., Imagawa, A., Shimada, A., et al. (2019) Genome-Wide Association Study Confirming a Strong Effect of HLA and Identifying Variants in CSAD\/lnc-ITGB7-1 on Chromosome 12q13.13 Associated With Susceptibility to Fulminant Type 1 Diabetes. Diabetes 68; 665\u2013675.","DOI":"10.2337\/db18-0314"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kawabata, Y. and Ikegami, H. (2020) Genetics of fulminant type 1 diabetes. Diabetol. Int. 11; 315\u2013322.","DOI":"10.1007\/s13340-020-00468-0"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Kitazawa, S. and Kitazawa, R. (2023) Prominent CD8-positive lymphocyte-associated insulitis immediately after onset of childbirth-related fulminant type 1 diabetes mellitus observed at autopsy. Pathol. Int. 73; 103\u2013105.","DOI":"10.1111\/pin.13299"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Koguchi, O., Nishimaki, H., Nakanishi, Y., Kobayashi, H., Ohni, S., Tang, X., et al. (2021) Altered Immunohistochemical Expression Patterns of HLA Class I during the Clinical Course of Cervical Intraepithelial Neoplasia. Acta Histochem. Cytochem. 54; 57\u201364.","DOI":"10.1267\/ahc.21-00010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Kyriacou, A., Melson, E., Chen, W. and Kempegowda, P. (2020) Is immune checkpoint inhibitor-associated diabetes the same as fulminant type 1 diabetes mellitus? Clin. Med. (Lond.). 20; 417\u2013423.","DOI":"10.7861\/clinmed.2020-0054"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 La Rocca, C., Carbone, F., Longobardi, S. and Matarese, G. (2014) The immunology of pregnancy: regulatory T cells control maternal immune tolerance toward the fetus. Immunol. Lett. 162; 41\u201348.","DOI":"10.1016\/j.imlet.2014.06.013"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Lee, J. Y., Lee, M. and Lee, S. K. (2011) Role of endometrial immune cells in implantation. Clin. Exp. Reprod. Med. 38; 119\u2013125.","DOI":"10.5653\/cerm.2011.38.3.119"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Lu, B., Teng, X., Fu, G., Bao, L., Tang, J., Shi, H., et al. (2019) Analysis of PD-L1 expression in trophoblastic tissues and tumors. Hum. Pathol. 84; 202\u2013212.","DOI":"10.1016\/j.humpath.2018.10.001"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Manohar, S., Ghamrawi, R., Chengappa, M., Goksu, B. N. B., Kottschade, L., Finnes, H., et al. (2020) Acute Interstitial Nephritis and Checkpoint Inhibitor Therapy: Single Center Experience of Management and Drug Rechallenge. Kidney360 1; 16\u201324.","DOI":"10.34067\/KID.0000152019"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Marsiglio, J., McPherson, J. P., Kovacsovics-Bankowski, M., Jeter, J., Vaklavas, C., Swami, U., et al. (2023) A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome. Front. Immunol. 14; 1229823.","DOI":"10.3389\/fimmu.2023.1229823"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Matsuura, N., Koh, G., Konishi, C., Minamino, S., Takahara, Y., Harada, H., et al. (2018) Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC. Cancer Immunol. Immunother. 67; 1417\u20131424.","DOI":"10.1007\/s00262-018-2203-3"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Minn, A. J. and Wherry, E. J. (2016) Combination Cancer Therapies with Immune Checkpoint Blockade: Convergence on Interferon Signaling. Cell 165; 272\u2013275.","DOI":"10.1016\/j.cell.2016.03.031"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Morad, G., Helmink, B. A., Sharma, P. and Wargo, J. A. (2021) Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184; 5309\u20135337.","DOI":"10.1016\/j.cell.2021.09.020"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19; 813\u2013824.","DOI":"10.1093\/intimm\/dxm057"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Sato, T., Takagi, K., Higuchi, M., Abe, H., Kojimahara, M., Sagawa, M., et al. (2022) Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. Acta Histochem. Cytochem. 55; 25\u201335.","DOI":"10.1267\/ahc.21-00075"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Seki, M., Kitano, S. and Suzuki, S. (2022) Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. Cancer Immunol. Immunother. 71; 769\u2013775.","DOI":"10.1007\/s00262-021-03053-9"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32 Sharma, P. and Allison, J. P. (2015) Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161; 205\u2013214.","DOI":"10.1016\/j.cell.2015.03.030"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., et al. (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186; 1652\u20131669.","DOI":"10.1016\/j.cell.2023.03.006"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Shen, X. and Zhao, B. (2018) Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362; k3529.","DOI":"10.1136\/bmj.k3529"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Singh, A. K., Stock, P. and Akbari, O. (2011) Role of PD-L1 and PD-L2 in allergic diseases and asthma. Allergy 66; 155\u2013162.","DOI":"10.1111\/j.1398-9995.2010.02458.x"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Tagliamento, M., Bironzo, P., Curcio, H., De Luca, E., Pignataro, D., Rapetti, S. G., et al. (2022) A systematic review and meta-analysis of trials assessing PD-1\/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma. Crit. Rev. Oncol. Hematol. 172; 103639.","DOI":"10.1016\/j.critrevonc.2022.103639"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37 Tocchetti, C. G., Farmakis, D., Koop, Y., Andres, M. S., Couch, L. S., Formisano, L., et al. (2024) Cardiovascular toxicities of immune therapies for cancer\u2014a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur. J. Heart. Fail. 26; 2055\u20132076.","DOI":"10.1002\/ejhf.3340"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38 Veras, E., Kurman, R. J., Wang, T. L. and Shih, I. M. (2017) PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases. Int. J. Gynecol. Pathol. 36; 146\u2013153.","DOI":"10.1097\/PGP.0000000000000305"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39 Wang, J., Han, T. and Zhu, X. (2024) Role of maternal-fetal immune tolerance in the establishment and maintenance of pregnancy. Chin. Med. J. (Engl.). 137; 1399\u20131406.","DOI":"10.1097\/CM9.0000000000003114"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40 Wood, H., Acharjee, A., Pearce, H., Quraishi, M. N., Powell, R., Rossiter, A., et al. (2021) Breastfeeding promotes early neonatal regulatory T-cell expansion and immune tolerance of non-inherited maternal antigens. Allergy 76; 2447\u20132460.","DOI":"10.1111\/all.14736"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41 Wu, H. M., Chen, L. H., Hsu, L. T. and Lai, C. H. (2022) Immune Tolerance of Embryo Implantation and Pregnancy: The Role of Human Decidual Stromal Cell- and Embryonic-Derived Extracellular Vesicles. Int. J. Mol. Sci. 23; 13382.","DOI":"10.3390\/ijms232113382"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42 Zeldovich, V. B. and Bakardjiev, A. I. (2012) Host defense and tolerance: unique challenges in the placenta. PLoS Pathog. 8; e1002804.","DOI":"10.1371\/journal.ppat.1002804"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43 Zezza, M., Kosinski, C., Mekoguem, C., Marino, L., Chtioui, H., Pitteloud, N., et al. (2019) Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports. BMC Endocr. Disord. 19; 144.","DOI":"10.1186\/s12902-019-0467-z"}],"container-title":["ACTA HISTOCHEMICA ET CYTOCHEMICA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ahc\/58\/1\/58_24-00056EP\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T05:05:20Z","timestamp":1740805520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ahc\/58\/1\/58_24-00056EP\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,27]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1267\/ahc.24-00056ep","relation":{},"ISSN":["0044-5991","1347-5800"],"issn-type":[{"value":"0044-5991","type":"print"},{"value":"1347-5800","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,27]]},"article-number":"24-00056EP"}}